Adaptive Biotechnologies
ADPT
26.28
-0.62
-2.30%
Adaptive Biotechnologies
US · ADPT
#2184 by market cap
Listed 2019
26.28
-0.62
-2.30%
Live - 5344 symbols - heartbeat 294s ago
· 2026-10-08 06:44
Pre-market
25.65
-2.40%
After-hours
26.28
0.00%
Overnight
26.15
-0.49%
- Market cap
- 4.19B
- P/E (TTM)i
- -65.70
- P/Bi
- 29.36
- EPSi
- -0.39
- Div yieldi
- 0.00%
- 52W posi
- 76%
Reader sentiment
Are you bullish or bearish on ADPT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.69, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +54.77% YoY
Margins
- Gross margin
- 74.24%
- Operating margin
- -20.62%
- Net margin
- -21.48%
Key ratios & quality
- Altman Z-Scorei
- 5.69
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 55.66M | 85.07M | 98.38M | 154.34M | 185.31M | 170.28M | 178.96M | 276.98M |
| Gross profit | 36.00M | 62.80M | 75.85M | 105.04M | 127.40M | 94.72M | 106.88M | 205.62M |
| Selling & admin expenses | 44.90M | 68.79M | 110.89M | 169.97M | 184.13M | 172.51M | 157.57M | 167.27M |
| Research & development | 39.16M | 70.71M | 116.07M | 142.34M | 141.76M | 122.12M | 102.95M | 93.77M |
| Operating profit | -49.76M | -78.39M | -152.82M | -208.97M | -200.19M | -201.61M | -155.34M | -57.12M |
| Pretax profit | -46.45M | -68.61M | -146.23M | -207.30M | -200.37M | -225.30M | -159.60M | -59.46M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -46.45M | -68.61M | -146.23M | -207.30M | -200.37M | -225.30M | -159.60M | -59.46M |
| Basic EPS | 0 | -1 | -1 | -1 | -1 | -2 | -1 | 0 |
| Diluted EPS | -0.44 | -1.01 | -1.11 | -1.48 | -1.40 | -1.56 | -1.08 | -0.39 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 52.44M | 58.88M | 93.97M | 71.68M | 70.87M | 71.55M |
| Gross profit | 35.46M | 40.88M | 75.82M | 53.46M | 52.17M | 51.39M |
| Selling & admin expenses | 40.45M | 41.36M | 41.43M | 44.04M | 47.33M | 47.58M |
| Research & development | 24.20M | 24.13M | 23.67M | 21.76M | 23.62M | 19.15M |
| Operating profit | -29.60M | -25.04M | 10.29M | -12.77M | -19.21M | -15.77M |
| Pretax profit | -29.83M | -25.59M | 9.55M | -13.58M | -20.02M | -39.94M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -29.83M | -25.59M | 9.55M | -13.58M | -20.02M | -39.94M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.20 | -0.17 | 0.06 | -0.09 | -0.13 | -0.25 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 180.72M | 612.69M | 726.91M | 402.75M | 562.15M | 410.19M | 283.75M | 300.19M |
| Cash & ST investments | 165.02M | 576.87M | 688.27M | 353.06M | 498.20M | 346.40M | 222.29M | 226.98M |
| Inventory | 7.84M | 9.07M | 14.06M | 19.26M | 14.45M | 14.45M | 8.44M | 9.82M |
| Total assets | 332.69M | 912.30M | 1.12B | 923.34M | 856.62M | 661.13M | 539.38M | 512.74M |
| Total current liabilities | 22.80M | 78.31M | 105.20M | 113.81M | 109.79M | 88.02M | 98.05M | 89.92M |
| Short-term debt | -- | -- | 3.53M | 5.06M | 9.23M | 9.38M | 10.24M | 8.92M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 590,800,000.00 | 341,263,000.00 | 373,148,000.00 | 319,242,000.00 | 392,519,000.00 | 352,856,000.00 | 336,891,000.00 | 287,735,000.00 |
| Total equity | -258.11M | 571.04M | 743.27M | 604.10M | 464.10M | 308.28M | 202.49M | 225.00M |
| Retained earnings | -295.91M | -365.48M | -511.61M | -718.89M | -919.08M | -1.14B | -1.30B | -1.36B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 256.49M | 261.86M | 281.44M | 300.19M | 291.81M | 420.56M |
| Cash & ST investments | 193.42M | 197.87M | 212.77M | 226.98M | 218.33M | 344.26M |
| Inventory | 8.68M | 8.40M | 9.93M | 9.82M | 11.21M | 10.50M |
| Total assets | 510.85M | 496.64M | 490.61M | 512.74M | 505.94M | 640.68M |
| Total current liabilities | 87.81M | 92.14M | 83.36M | 89.92M | 87.01M | 87.71M |
| Short-term debt | 10.46M | 9.96M | 9.44M | 8.92M | 8.51M | 8.82M |
| Long-term debt | -- | -- | -- | -- | -- | 334.88M |
| Total liabilities | 320,631,000.00 | 317,101,000.00 | 286,357,000.00 | 287,735,000.00 | 281,702,000.00 | 490,016,000.00 |
| Total equity | 190.22M | 179.54M | 204.25M | 225.00M | 224.24M | 150.66M |
| Retained earnings | -1.33B | -1.36B | -1.35B | -1.36B | -1.38B | -1.42B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -32.26M | 205.40M | -149.68M | -192.73M | -183.95M | -156.32M | -95.21M | -45.99M |
| Depreciation & amortization | 6.00M | 7.79M | 8.47M | 13.95M | 20.92M | 22.23M | 19.26M | 17.83M |
| Free cash flow | -38.56M | 194.20M | -168.49M | -254.47M | -200.29M | -167.02M | -98.88M | -48.95M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 320.85M | 272.16M | -- | -- | -- | -- | -- |
| Ending cash balance | 55.09M | 98.71M | 125.57M | 141.20M | 92.43M | 68.00M | 50.82M | 73.18M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -28.48M | -12.43M | -7.13M | 2.06M | -9.54M | -6.40M |
| Depreciation & amortization | 4.73M | 4.50M | 4.41M | 4.20M | 3.84M | 3.70M |
| Free cash flow | -29.74M | -13.09M | -7.54M | 1.42M | -10.33M | -7.58M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 53.36M | 45.88M | 57.72M | 73.18M | 80.29M | 172.60M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -44.46 | -22.25 | -30.77 | -37.48 | -58.31 | -62.41 | -28.23 |
| ROA %i | -13.33 | -11.18 | -14.42 | -20.32 | -22.49 | -29.68 | -26.57 | -11.31 |
| ROIC %i | -- | -41.10 | -20.90 | -26.67 | -31.06 | -46.35 | -46.46 | -19.38 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -38.66 | -42.25 | -43.44 |
| EBIT margin %i | -89.39 | -92.15 | -155.33 | -135.39 | -105.84 | -124.21 | -82.71 | -17.21 |
| FCF / sales %i | -- | 228.28 | -- | -- | -- | -- | -- | -- |
| Current ratioi | 7.93 | 7.82 | 6.91 | 3.54 | 5.12 | 4.66 | 2.89 | 3.34 |
| Quick ratioi | 7.45 | 7.53 | 6.64 | 3.26 | 4.90 | 4.37 | 2.69 | 3.08 |
| Debt / assetsi | 0.00 | 4.01 | 9.66 | 12.10 | 12.61 | 14.94 | 16.57 | 15.44 |
| LT debt / equityi | -- | 6.41 | 14.04 | 17.66 | 21.28 | 28.98 | 39.05 | 32.10 |
| Interest coveragei | -- | -- | -- | -- | -46.28 | -15.33 | -12.78 | -4.05 |
| Revenue CAGR (3Y) %i | -- | -- | 36.78 | 40.49 | 29.63 | 20.06 | 5.06 | 14.34 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -60.96 | -57.55 | -37.18 | -28.23 | -24.43 | -39.58 |
| ROA %i | -25.08 | -22.42 | -15.18 | -11.31 | -9.77 | -11.23 |
| ROIC %i | -44.19 | -40.38 | -25.99 | -19.38 | -16.37 | -14.94 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -68.80 | -53.36 | -26.83 | -17.21 | -12.82 | -17.04 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.92 | 2.84 | 3.38 | 3.34 | 3.35 | 4.79 |
| Quick ratioi | 2.70 | 2.63 | 3.09 | 3.08 | 3.06 | 4.49 |
| Debt / assetsi | 17.01 | 16.99 | 16.67 | 15.44 | 15.34 | 64.07 |
| LT debt / equityi | 40.14 | 41.41 | 35.40 | 32.10 | 31.95 | 281.06 |
| Interest coveragei | -11.35 | -9.32 | -5.76 | -4.05 | -3.22 | -4.56 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Minimal Residual Disease (MRD) is the largest reported line at 84.13% of revenue, across 2 reported segments.
- The next-largest line, Immune Medicine, is a distant second at 15.87% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Minimal Residual Disease (MRD)84.13%
Immune Medicine15.87%
Quote time 2026-10-08 06:44:39 · For reference only, not investment advice and not tailored to your situation.